文献速递免疫规划传染病防控与疫情报告慢病防控与筛查

伊朗多发性硬化患者接种首剂国药BBIBP-CorV疫苗后的不良事件报告

Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV.
PubMed 文献 · Vaccine · 2021-09-23

该研究通过社交网络向伊朗多发性硬化(MS)患者发放谷歌表单,收集2021年5月1日至22日接种首剂国药BBIBP-CorV疫苗后的不良事件,共纳入583例。未报告严重不良事件,350例(60%)报告至少一种主诉(多为暂时性),以全身症状(51%)和头痛(9%)最常见;仅5例(0.9%)报告MS复发。性别和既往COVID-19感染与报告症状相关(p值小于0.05)。

要点

  • 583例伊朗MS患者接种首剂国药疫苗后未报告严重不良事件。
  • 60%报告至少一种主诉,多为暂时性,全身症状和头痛最常见。
  • 仅0.9%报告MS复发,MS加重与发热相关且为次要事件。

核心结论

  • 伊朗MS患者接种首剂国药BBIBP-CorV疫苗后未报告严重不良事件,不良事件多为暂时性,MS复发少见。

研究设计与样本

  • 研究于2021年5月1日至5月22日通过社交网络向伊朗MS患者发送谷歌表单链接,纳入583例接种首剂国药BBIBP-CorV疫苗的MS患者,收集不良事件。

主要发现

  • 350例(60%)报告至少一种主诉,多为暂时性;全身症状(不适、疲劳、发热、寒战和全身疼痛)占51%,头痛占9%。
  • 仅5例(0.9%)报告接种后MS复发;MS加重是与发热相关的次要事件。
  • 性别和既往COVID-19感染与报告症状相关(p值小于0.05)。

临床怎么用

  • 可为MS患者接种国药BBIBP-CorV疫苗的安全性咨询提供参考,提示不良事件多为暂时性且严重事件罕见。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

MS patients were one of the first populations vaccinated in Iran. To date, the most used vaccine brand on Iranian MS patients is Sinopharm COVID-19 vaccine. Here is the first study on the adverse events after the first dose of Sinopharm vaccine on 583 Iranian MS patients. A Google form link was sent to MS patients through social networks, between May 1, 2021 and May 22, 2021. No serious adverse event was reported. At least one complaint (mostly transient) was reported by 350 (60%) of vaccine recipients. Constitutional symptoms (malaise, fatigue, fever, shivering, & generalized body pain) (51%) and headache (9%) were the most reported complaints. We found a relation between gender and prior infection with COVID-19 and reported symptoms (p value less than 0.05). Only five recipients (0.9%) reported MS relapse after vaccination. MS worsening was a minor incident related to fever.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ali Sahraian M, Ghadiri F, Azimi A, et al. Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV. Vaccine. 2021. PMID: 34579974. doi:10.1016/j.vaccine.2021.09.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。